CB

Colin Biggin

Clarity Pharmaceuticals Ltd | Chief Executive Officer, Managing Director
Dr Biggin has over 15 years of radiopharmaceutical development and commercialisation experience. Dr Biggin previously served with Algeta ASA during the development and commercialisation of its product Xofigo for metastatic prostate cancer, which was approved by the US FDA in 2013. Prior to joining the Company, Dr Biggin also consulted to a range of biotech and large pharmaceutical companies developing radiopharmaceuticals.

Company and Roles

Company
Title
Tenure
Since
CU6
CU6
Clarity Pharmaceuticals Ltd
  • Chief Executive Officer
  • Managing Director
5yrs, 5mthOct 2019

Holding

Company
Last Notice
Direct Shares
Indirect Shares
Options
Convertibles
CU6
CU6
Clarity Pharmaceuticals Ltd
20/11/244,334,085N/A3,052,761N/A

Transactions

Company
Date
Type
Amount
Price
Value
Notes
CU6
CU6
Clarity Pharmaceuticals Ltd
20/11/24
Issued
285,918$2.756$787,875Issue of options
CU6
CU6
Clarity Pharmaceuticals Ltd
01/10/24
Exercise
1,200,000$0.825$990,000Exercise of options
CU6
CU6
Clarity Pharmaceuticals Ltd
01/10/24
Buy
1,084,321$0.913$990,000Exercise of options
CU6
CU6
Clarity Pharmaceuticals Ltd
07/08/24
Buy
905,625$0.668$605,000Exercise of options
CU6
CU6
Clarity Pharmaceuticals Ltd
07/08/24
Exercise
1,000,000$0.605$605,000Exercise of options